drug

tebapivat

1 story · latest Jul 30, 2026

Status: Investigational
Code: AG-946
Trials: 2 registered trials in coverage

Relationships

Developed by Agios Pharmaceuticals, Inc.

Timeline

Agios reports Q2 2026 results, sickle cell filing gets FDA priority review

Jul 30Quarterly updateAgios Pharmaceuticals, Inc.mitapivat

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.